{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-145405","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.079261+00:00","generated_at":"2026-05-18T22:54:46.464687+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67","bullets":["Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.","Purchasers include existing healthcare-focused institutional investors, executive officers, and directors.","Net proceeds to support pre-commercialization and launch readiness for CAN-2409 in prostate cancer; BLA submission planned Q4 2026.","Insider participation signals confidence in Candel's strategy and pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-145405","json":"https://secwatch.observer/filing/0001193125-25-145405.json","markdown":"https://secwatch.observer/filing/0001193125-25-145405.md","text":"https://secwatch.observer/filing/0001193125-25-145405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/0001193125-25-145405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/d34398d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:54:46.464687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}